Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Ferguson
FERG
|
+$740M |
| 2 |
Uber
UBER
|
+$498M |
| 3 |
DexCom
DXCM
|
+$449M |
| 4 |
Meta Platforms (Facebook)
META
|
+$312M |
| 5 |
Autodesk
ADSK
|
+$305M |
Top Sells
| 1 |
Salesforce
CRM
|
+$1.28B |
| 2 |
Apple
AAPL
|
+$916M |
| 3 |
PayPal
PYPL
|
+$610M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$477M |
| 5 |
Accenture
ACN
|
+$391M |
Sector Composition
| 1 | Technology | 30.51% |
| 2 | Healthcare | 19.12% |
| 3 | Consumer Discretionary | 11.48% |
| 4 | Financials | 10.31% |
| 5 | Communication Services | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Lear
LEA
$5.91B
| $2.82M | ﹤0.01% |
15,543
+2,613
| +20% | +$474K |
|
1127
Pentair
PNR
$17.9B
| $2.78M | ﹤0.01% |
44,539
-6,544
| -13% | -$408K |
|
1128
PTC
PTC
$24.4B
| $2.75M | ﹤0.01% |
19,960
+480
| +2% | +$66.1K |
|
1129
Bausch Health
BHC
$2.67B
| $2.74M | ﹤0.01% |
86,647
-25,807
| -23% | -$817K |
|
1130
Neogen
NEOG
$1.24B
| $2.73M | ﹤0.01% |
+61,488
| New | +$2.73M |
|
|
KDNY
1131
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.7M | ﹤0.01% |
173,551
| – | – |
|
1132
Lincoln National
LNC
$7.88B
| $2.69M | ﹤0.01% |
43,224
-1,663
| -4% | -$104K |
|
1133
Pennant Group
PNTG
$858M
| $2.67M | ﹤0.01% |
58,352
+52,931
| +976% | +$2.42M |
|
1134
Popular Inc
BPOP
$8.39B
| $2.65M | ﹤0.01% |
37,670
+32,199
| +589% | +$2.26M |
|
1135
Open Text
OTEX
$8.7B
| $2.65M | ﹤0.01% |
55,462
| – | – |
|
1136
Dianthus Therapeutics
DNTH
$1.14B
| $2.63M | ﹤0.01% |
+13,907
| New | +$2.63M |
|
1137
Supernus Pharmaceuticals
SUPN
$2.58B
| $2.59M | ﹤0.01% |
98,963
+24,620
| +33% | +$645K |
|
|
SYNH
1138
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $2.57M | ﹤0.01% |
33,898
-74,899
| -69% | -$5.68M |
|
1139
Alnylam Pharmaceuticals
ALNY
$63.2B
| $2.57M | ﹤0.01% |
18,183
-72,072
| -80% | -$10.2M |
|
1140
GeoPark
GPRK
$322M
| $2.54M | ﹤0.01% |
158,866
| – | – |
|
|
FPRX
1141
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $2.52M | ﹤0.01% |
+66,786
| New | +$2.52M |
|
|
FRTA
1142
DELISTED
Forterra, Inc
FRTA
| $2.51M | ﹤0.01% |
+108,008
| New | +$2.51M |
|
1143
Iovance Biotherapeutics
IOVA
$858M
| $2.48M | ﹤0.01% |
78,211
+60,207
| +334% | +$1.91M |
|
1144
LKQ Corp
LKQ
$8.31B
| $2.44M | ﹤0.01% |
57,725
-120,417
| -68% | -$5.1M |
|
1145
Southern Copper
SCCO
$81.1B
| $2.43M | ﹤0.01% |
37,596
-23,517
| -38% | -$1.52M |
|
1146
CytomX Therapeutics
CTMX
$345M
| $2.42M | ﹤0.01% |
+312,667
| New | +$2.42M |
|
1147
Teva Pharmaceuticals
TEVA
$22.6B
| $2.41M | ﹤0.01% |
208,473
+5,326
| +3% | +$61.5K |
|
1148
Antero Midstream
AM
$8.74B
| $2.4M | ﹤0.01% |
265,874
+1,662
| +0.6% | +$15K |
|
|
CELL
1149
DELISTED
PhenomeX Inc. Common Stock
CELL
| $2.4M | ﹤0.01% |
47,754
-8,875
| -16% | -$446K |
|
1150
American Homes 4 Rent
AMH
$12.8B
| $2.39M | ﹤0.01% |
71,491
+20,881
| +41% | +$697K |
|